Matches in SemOpenAlex for { <https://semopenalex.org/work/W3162880659> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W3162880659 endingPage "242" @default.
- W3162880659 startingPage "239" @default.
- W3162880659 abstract "We retrospectively evaluated the incidence of skin immune-related adverse effects (irAEs) in patients treated with pembrolizumab (PMB) and explored and the relationship between skin irAEs and PMB efficacy. Thirty-two patients with non-small cell lung cancer treated with PMB between April 2017 and May 2018 were enrolled. The patients were separated into two groups, namely, skin irAEs and no-skin irAEs group. We investigated the ratio and degree of express skin irAEs, period of skin irAEs and treatment, and the PFS between the two groups. Additionally, we evaluated the PFS between the irAE and no-irAEs groups. The median patient age was 76.5 (range 56-92) years. The European Cooperative Oncology Group Performance Status (ECOG PS) score of 26, 5, and 1 was 0-1, 2, and 3, respectively. The male/female ratio was 23/9. In terms of clinical stages, 6, 21, and 5 patients were in stages III and IV, and postoperative relapse, respectively. Skin irAEs were observed in 10 patients (31%). The progression-free survival of patients with skin irAEs (median, 390 days) was longer than that of patients without skin irAEs (median, 128.5 days). Overall, we suggested a significant association between skin irAEs and the efficacy of PMB in treating non-small cell lung cancer. As skin irAEs can be an indicator of treatment efficacy, it is important for medical staff, including pharmacists, to closely observe these adverse events." @default.
- W3162880659 created "2021-05-24" @default.
- W3162880659 creator A5007095901 @default.
- W3162880659 creator A5013340536 @default.
- W3162880659 creator A5023286374 @default.
- W3162880659 creator A5031363941 @default.
- W3162880659 creator A5055962201 @default.
- W3162880659 creator A5080338484 @default.
- W3162880659 creator A5086736337 @default.
- W3162880659 creator A5087903422 @default.
- W3162880659 date "2021-05-01" @default.
- W3162880659 modified "2023-09-23" @default.
- W3162880659 title "Association between immune-related dermatologic adverse events and efficacy of pembrolizumab in non-small cell lung cancer patients." @default.
- W3162880659 doi "https://doi.org/10.1691/ph.2021.01018" @default.
- W3162880659 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33964999" @default.
- W3162880659 hasPublicationYear "2021" @default.
- W3162880659 type Work @default.
- W3162880659 sameAs 3162880659 @default.
- W3162880659 citedByCount "3" @default.
- W3162880659 countsByYear W31628806592022 @default.
- W3162880659 countsByYear W31628806592023 @default.
- W3162880659 crossrefType "journal-article" @default.
- W3162880659 hasAuthorship W3162880659A5007095901 @default.
- W3162880659 hasAuthorship W3162880659A5013340536 @default.
- W3162880659 hasAuthorship W3162880659A5023286374 @default.
- W3162880659 hasAuthorship W3162880659A5031363941 @default.
- W3162880659 hasAuthorship W3162880659A5055962201 @default.
- W3162880659 hasAuthorship W3162880659A5080338484 @default.
- W3162880659 hasAuthorship W3162880659A5086736337 @default.
- W3162880659 hasAuthorship W3162880659A5087903422 @default.
- W3162880659 hasConcept C120665830 @default.
- W3162880659 hasConcept C121332964 @default.
- W3162880659 hasConcept C121608353 @default.
- W3162880659 hasConcept C126322002 @default.
- W3162880659 hasConcept C141071460 @default.
- W3162880659 hasConcept C16005928 @default.
- W3162880659 hasConcept C197934379 @default.
- W3162880659 hasConcept C2776256026 @default.
- W3162880659 hasConcept C2777701055 @default.
- W3162880659 hasConcept C2777789703 @default.
- W3162880659 hasConcept C2780057760 @default.
- W3162880659 hasConcept C61511704 @default.
- W3162880659 hasConcept C71924100 @default.
- W3162880659 hasConcept C90924648 @default.
- W3162880659 hasConceptScore W3162880659C120665830 @default.
- W3162880659 hasConceptScore W3162880659C121332964 @default.
- W3162880659 hasConceptScore W3162880659C121608353 @default.
- W3162880659 hasConceptScore W3162880659C126322002 @default.
- W3162880659 hasConceptScore W3162880659C141071460 @default.
- W3162880659 hasConceptScore W3162880659C16005928 @default.
- W3162880659 hasConceptScore W3162880659C197934379 @default.
- W3162880659 hasConceptScore W3162880659C2776256026 @default.
- W3162880659 hasConceptScore W3162880659C2777701055 @default.
- W3162880659 hasConceptScore W3162880659C2777789703 @default.
- W3162880659 hasConceptScore W3162880659C2780057760 @default.
- W3162880659 hasConceptScore W3162880659C61511704 @default.
- W3162880659 hasConceptScore W3162880659C71924100 @default.
- W3162880659 hasConceptScore W3162880659C90924648 @default.
- W3162880659 hasIssue "5" @default.
- W3162880659 hasLocation W31628806591 @default.
- W3162880659 hasOpenAccess W3162880659 @default.
- W3162880659 hasPrimaryLocation W31628806591 @default.
- W3162880659 hasRelatedWork W10914099 @default.
- W3162880659 hasRelatedWork W16005443 @default.
- W3162880659 hasRelatedWork W18451002 @default.
- W3162880659 hasRelatedWork W19887974 @default.
- W3162880659 hasRelatedWork W20970363 @default.
- W3162880659 hasRelatedWork W3197746 @default.
- W3162880659 hasRelatedWork W5091422 @default.
- W3162880659 hasRelatedWork W7644388 @default.
- W3162880659 hasRelatedWork W7661019 @default.
- W3162880659 hasRelatedWork W18591290 @default.
- W3162880659 hasVolume "76" @default.
- W3162880659 isParatext "false" @default.
- W3162880659 isRetracted "false" @default.
- W3162880659 magId "3162880659" @default.
- W3162880659 workType "article" @default.